Drug intelligence / Profile preview

NGR-hTNF + cisplatin + gemcitabine

Development stage: Preclinical
Lead developer: MolMed
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of NGR-hTNF plus cisplatin and gemcitabine. Cisplatin and gemcitabine are established chemotherapy agents that have shown efficacy in various cancers, particularly pancreatic cancer. Cisplatin is a platinum-based drug that destroys quickly dividing cells by damaging DNA, while gemcitabine is a nucleoside analog that also targets rapidly dividing cancer cells. The combination of cisplatin and gemcitabine has demonstrated efficacy in treating pancreatic cancer, particularly in patients with BRCA/PALB2 mutations.

Targets

DNAANPEP (Aminopeptidase N)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)

Beyond the preview

Go deeper on NGR-hTNF + cisplatin + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGR-hTNF + cisplatin + gemcitabine.

Explore the full profile